Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder

International Journal of Geriatric Psychiatry

Volumn 28, Issue 6, 2013, Pages 615-625

  Mezhebovsky, Irina ^a   Mägi, Kairi ^b   She, Fahua ^c   Datto, Catherine ^c   Eriksson, Hans ^d  

^a Boston Clinical Trials Inc   (United States)

^b TARTU UNIVERSITY HOSPITAL   (Estonia)

^c ASTRAZENECA   (United Kingdom)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

atypical antipsychotic; generalized anxiety disorder; older population; quetiapine XR

Indexed keywords

PLACEBO; QUETIAPINE;

AGED; AKATHISIA; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DSM-IV; DYSKINESIA; ESTONIA; EXTRAPYRAMIDAL SYNDROME; FEMALE; FOLLOW UP; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HEADACHE; HUMAN; LETHARGY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; MUSCLE HYPERTONIA; NAUSEA; PITTSBURGH SLEEP QUALITY INDEX; POLAND; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REMISSION; RESTLESSNESS; RUSSIAN FEDERATION; SEDATION; SIDE EFFECT; SLEEP QUALITY; SOMNOLENCE; TREMOR; UKRAINE; UNITED STATES; VISUAL ANALOG SCALE; XEROSTOMIA;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; DELAYED-ACTION PREPARATIONS; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PATIENT SATISFACTION; QUALITY OF LIFE;

EID: 84877580124     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.3867     Document Type: Article

References (41)

1. Adson DE, Kushner MG, Eiben KM, et al,. 2004. Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors. Depress Anxiety 19: 121-126.
2. Alwahhabi F,. 2003. Anxiety symptoms and generalized anxiety disorder in the elderly: a review. Harv Rev Psychiatry 11: 180-193.
3. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. American Psychiatric Association: Washington, DC.
4. AstraZeneca. 2012. Seroquel XR (quetiapine fumarate) extended-release tablets-US prescribing information. (Available from: http://www1.astrazeneca-us. com/pi/seroquelxr.pdf, Accessed 26 Apr 2012).
5. Bandelow B, Chouinard G, Bobes J, et al,. 2010. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol 13: 305-320.
6. Bandelow B, Zohar J, Hollander E, et al,. 2008. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders-First Revision. World J Biol Psychiatry 9: 248-312.
7. Canadian Psychiatric Association. 2006. Management of anxiety disorders. Can J Psychiatry 51 (Suppl 2): 1S-93S.
8. Casey DE,. 2006. Implications of the CATIE trial on treatment: extrapyramidal symptoms. CNS Spectr 11: 25-31.
9. Cochen V, Arbus C, Soto ME, et al,. 2009. Sleep disorders and their impacts on healthy, dependent, and frail older adults. J Nutr Health Aging 13: 322-329.
10. Davidson J, Allgulander C, Pollack MH, et al,. 2008. Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies. Hum Psychopharmacol 23: 519-526.
11. Davidson JR,. 2009. First-line pharmacotherapy approaches for generalized anxiety disorder. J Clin Psychiatry 70 (Suppl 2): 25-31.
12. Galynker I, Khan A, Grebchenko Y, et al,. 2005. Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression. J Clin Psychiatry 66: 544.
13. Guy W,. 1976. Clinical Global Impressions. In ECDEU assessment manual for psychopharmacology publication. US Department of Health, Education and Welfare: Washington, DC; 218-222.
14. Hamilton M,. 1959. The assessment of anxiety states by rating. Br J Med Psychol 32: 50-55.
15. Joo JH, Lenze EJ, Mulsant BH, et al,. 2002. Risk factors for falls during treatment of late-life depression. J Clin Psychiatry 63: 936-941.
16. Kahn RS, Schulz SC, Palazov VD, et al,. 2007. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68: 832-842.
17. Katz IR, Reynolds CF, III, Alexopoulos GS, et al,. 2002. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials. J Am Geriatr Soc 50: 18-25.
18. Katzman MA,. 2009. Current considerations in the treatment of generalized anxiety disorder. CNS Drugs 23: 103-120.
19. Katzman MA, Brawman-Mintzer O, Reyes EB, et al,. 2011. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. Int Clin Psychopharmacol 26: 11-24.
20. Katzman MA, Vermani M, Jacobs L, et al,. 2008. Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. J Anxiety Disord 22: 1480-1486.
21. Kemmler G, Hummer M, Widschwendter C, et al,. 2005. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry 62: 1305-1312.
22. Khan A, Joyce M, Atkinson S, et al,. 2011. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol 31: 418-428.
23. Lane RM,. 1998. SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. J Psychopharmacol 12: 192-214.
24. Lenze EJ, Rollman BL, Shear MK, et al,. 2009. Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial. JAMA 301: 295-303.
25. Lydiard RB, Rickels K, Herman B, et al,. 2010. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int J Neuropsychopharmacol 13: 229-241.
26. Merideth C, Cutler AJ, She F, et al,. 2012. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study. Int Clin Psychopharmacol 27: 40-54.
27. Michelson D, Fava M, Amsterdam J, et al,. 2000. Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. Br J Psychiatry 176: 363-368.
28. Montgomery SA, Åsberg M,. 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-389.
29. Neutel CI, Hirdes JP, Maxwell CJ, et al,. 1996. New evidence on benzodiazepine use and falls: the time factor. Age Ageing 25: 273-278.
30. NICE guidelines. 2007. Clinical Guideline 22 (amended) Anxiety: management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. Available from: http://www.nice.org.uk/nicemedia/pdf/ CG022NICEguidelineamended.pdf [Accessed: September 27, 2012].
31. Osterberg L, Blaschke T,. 2005. Adherence to medication. N Engl J Med 353: 487-497.
32. Pinson L, Gray GE,. 2003. Psychopharmacology: number needed to treat: an underused measure of treatment effect. Psychiatr Serv 54: 145-146, 154.
33. Rosenbaum JF, Fava M, Hoog SL, et al,. 1998. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 44: 77-87.
34. Salzman C,. 2004. Treatment of late-life disordered behaviour, agitation and psychosis. In Clinical geriatric psychopharmacology. Lippincott, Williams and Wilkins: Philadelphia, PA; 117-195.
35. Sheehan DV, Lecrubier Y, Sheehan KH, et al,. 1998. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 (Suppl 20): 22-33.
36. Snyder AG, Stanley MA, Novy DM, et al,. 2000. Measures of depression in older adults with generalized anxiety disorder: a psychometric evaluation. Depress Anxiety 11: 114-120.
37. Weisler R, Joyce M, McGill L, et al,. 2009. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr 14: 299-313.
38. Wetherell JL, Le RH, Gatz M,. 2003. DSM-IV criteria for generalized anxiety disorder in older adults: distinguishing the worried from the well. Psychol Aging 18: 622-627.
39. Wittchen HU,. 2002. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 16: 162-171.
40. Wittchen HU, Kessler RC, Beesdo K, et al,. 2002. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 63 (Suppl 8): 24-34.
41. Zimmermann U, Kraus T, Himmerich H, et al,. 2003. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 37: 193-220.